 |
306 Products |  |
1129 Diseases | | 306 Products |
|
4023 Trials |  |
219432 News |  |
| «12...1112131415161718192021...26722673» |
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly
ERBIOTAX (TTCC-2022-02): A phase II, multicenter, randomized study of cetuximab with or without weekly paclitaxel after progression on first-line pembrolizumab plus platinum/5-FU in recurrent or metastatic head and neck squamous cell carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 585a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1948;
P2
Funded by Merck, S.L.U., Madrid, Spain, an affiliate of Merck KGaA, Darmstadt, Germany, Clinical Trial Registration Number: NCT06856213 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD), Cyramza (ramucirumab) / Eli Lilly
An open-label, randomized phase 2 trial of ramucirumab and pembrolizumab versus pembrolizumab as first-line therapy for PD-L1 (Hall A - Posters and Exhibits; Poster Bd #: 483) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1928;
P2
Funded by Merck, S.L.U., Madrid, Spain, an affiliate of Merck KGaA, Darmstadt, Germany, Clinical Trial Registration Number: NCT06856213 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Joseph Sanchez Foundation Eli Lilly Clinical Trial Registration Number: NCT05980000 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from the adenoid cystic cohort. (Hall A - Posters and Exhibits; Poster Bd #: 580) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1921;
P2
Funded by Joseph Sanchez Foundation Eli Lilly Clinical Trial Registration Number: NCT05980000 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Merck Clinical Trial Registration Number: NCT04895735 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- ficerafusp alfa (BCA101) / Bicara Therapeutics
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1 (Hall A - Posters and Exhibits; Poster Bd #: 584a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1920;
P2/3
Funded by Study funded by Bicara Therapeutics Inc. Clinical Trial Registration Number: NCT06788990 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- etakafusp alfa (AB248) / Asher Biotherap
Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies. (Hall A - Posters and Exhibits; Poster Bd #: 406) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1906;
P1
Clinical Trial Registration Number: NCT06788990 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Asherbio Therapeutics Clinical Trial Registration Number: NCT05653882 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD), Lymphir (denileukin diftitox-cxdl) / Citius Oncology
Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results. (Hall A - Posters and Exhibits; Poster Bd #: 354) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1895;
P1/2
Funded by Citius Oncology Inc. Clinical Trial Registration Number: NCT05200559 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- PLN-101095 / Pliant Therapeutics
Cohort expansion of a phase I study of PLN-101095, a first-in-class dual ?v?8/?v?1 integrin inhibitor, in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI). (Hall A - Posters and Exhibits; Poster Bd #: 467b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1892;
P1
Funded by Pliant Therapeutics, Inc. Clinical Trial Registration Number: NCT06270706 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Phase I study of zeaxanthin alone or in combination with pembrolizumab in metastatic solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 470b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1885;
P1
Funded by Dr. Richard Rosen Cancer Research Fund Clinical Trial Registration Number: NCT05232409 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- sunekafusp alpha (ANV600) / Anaveon
Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R-?? agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 377) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1857;
P1/2
Richard Rosen Cancer Research Fund Clinical Trial Registration Number: NCT05232409 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Anaveon AG Clinical Trial Registration Number: NCT06470763 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Oncopore (ruxotemitide) / Verrica
Safety and efficacy of intratumoral (IT) ruxotemitide (LTX 315) in combination with pembrolizumab in patients with unresectable advanced melanoma or triple-negative breast cancer (TNBC). (Hall A - Posters and Exhibits; Poster Bd #: 392) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1853;
P1, P2
Funded by Anaveon AG Clinical Trial Registration Number: NCT06470763 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT01986426 and NCT04796194 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- tosposertib (NCE 401) / Tium Bio, Chiesi
Phase IIa study of tosposertib, a dual TGF?RI and VEGFR2 inhibitor, in combination with pembrolizumab in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). (Hall A - Posters and Exhibits; Poster Bd #: 425) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1841;
P1/2
Clinical Trial Registration Number: NCT01986426 and NCT04796194 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by TiumBio Co., Ltd Clinical Trial Registration Number: NCT05784688 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Immunologic and clinical outcomes of perfluoroalkyl substances (PFAS) exposure in solid tumors treated with pembrolizumab. (Hall A - Posters and Exhibits; Poster Bd #: 329) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1800;
Funded by TiumBio Co., Ltd Clinical Trial Registration Number: NCT05784688 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- BI-1808 / BioInvent
BI?1808 + pembrolizumab: Responses to a chemotherapy?free regimen in advanced ovarian cancer. (Hall A - Posters and Exhibits; Poster Bd #: 395) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1766;
P1/2
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT04752826 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer. (Hall A - Posters and Exhibits; Poster Bd #: 121) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1666;
Clinical Trial Registration Number: NCT04752826 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Aidixi (disitamab vedotin) / Pfizer
Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab (Hall A - Posters and Exhibits; Poster Bd #: 225a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1570;
P3
Funded by RemeGen Co., Ltd. Clinical Trial Registration Number: NCT07315750 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: Outcomes from the microsatellite instability-high population of the phase 3 KEYNOTE-585 study. (Hall A - Posters and Exhibits; Poster Bd #: 57) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1566;
P3
Clinical Trial Registration Number: NCT07315750 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03221426 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Impact of HSPA6 on lenvatinib resistance in HCC via phase separation (Hall A - Posters and Exhibits; Poster Bd #: 102) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1536;
Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03221426 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
KEYNOTE-811: 6-year median follow-up of pembrolizumab plus trastuzumab and chemotherapy for previously untreated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 23) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1529;
P3
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03615326 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Enweida (envafolimab) / 3DMed, Ascletis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A multicenter, single-arm, open-label, phase II study (ENLIGHTEN study). (Hall A - Posters and Exhibits; Poster Bd #: 135) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1528;
P2
Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03615326 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by State Key Program of National Natural Science Foundation of China, National Natural Science Foundation of China, National Natural Science Foundation of China, Key Area Research and Development Program of Guangdong Province, Science and Technology Program of Guangzhou, China Clinical Trial Registration Number: NCT05410197 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Correlative analysis of phase II trial of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 140) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1527;
P2
Funded by State Key Program of National Natural Science Foundation of China, National Natural Science Foundation of China, National Natural Science Foundation of China, Key Area Research and Development Program of Guangdong Province, Science and Technology Program of Guangzhou, China Clinical Trial Registration Number: NCT05410197 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT03991832 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD), Ziihera (zanidatamab-hrii) / Jazz
Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1 (Hall A - Posters and Exhibits; Poster Bd #: 224b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1519;
P2
Clinical Trial Registration Number: NCT03991832 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by The Frankfurt Institute of Clinical Cancer Research (IKF) Jazz Pharmaceuticals Clinical Trial Registration Number: NCT07176312 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca
Durvalumab or pembrolizumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy for advanced cholangiocarcinoma: A meta-analysis. (Hall A - Posters and Exhibits; Poster Bd #: 143) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1506;
Funded by The Frankfurt Institute of Clinical Cancer Research (IKF) Jazz Pharmaceuticals Clinical Trial Registration Number: NCT07176312 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Yttrium-90 SIRT followed by lenvatinib plus sintilimab for unresectable intermediate-to-advanced hepatocellular carcinoma: Phase II SIRLENS-90 trial. (Hall A - Posters and Exhibits; Poster Bd #: 132) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1495;
P2
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by China zhongguancun Precision Medicine science and technology foundation Clinical Trial Registration Number: NCT05992584 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Sequential bTAE-HAIC combined with lenvatinib and sintilimab for infiltrative hepatocellular carcinoma: A single-center perspective. (Hall A - Posters and Exhibits; Poster Bd #: 114) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1469;
P=N/A
Funded by China zhongguancun Precision Medicine science and technology foundation Clinical Trial Registration Number: NCT05992584 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06070636 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Neoadjuvant radiotherapy combined with lenvatinib and sintilimab in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus: An open-label, single-arm, multicenter, prospective phase I clinical trial. (Hall A - Posters and Exhibits; Poster Bd #: 96) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1428;
P1
Clinical Trial Registration Number: NCT06070636 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT05225116 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus: A target trial emulation study (CHANCE 2416). (Hall A - Posters and Exhibits; Poster Bd #: 115) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1403;
P
Clinical Trial Registration Number: NCT05225116 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06631326 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD), talabostat (BXCL701) / BioXcel
BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial. (Hall A - Posters and Exhibits; Poster Bd #: 184) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1358;
P2
Clinical Trial Registration Number: NCT06631326 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by BioXcel Therapeutics Merck Ruesch Center for the Cure of Gastrointestinal Cancers Clinical Trial Registration Number: NCT05558982 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial. (Hall A - Posters and Exhibits; Poster Bd #: 106) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1345;
P=N/A
Funded by BioXcel Therapeutics Merck Ruesch Center for the Cure of Gastrointestinal Cancers Clinical Trial Registration Number: NCT05558982 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06061276 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- CDX-1140 / Celldex, Keytruda (pembrolizumab) / Merck (MSD)
A phase I/II study of CDX-1140, a CD40 agonist, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results. (Hall A - Posters and Exhibits; Poster Bd #: 112) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1343;
P1/2
Clinical Trial Registration Number: NCT06061276 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT05849480 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Tukysa (tucatinib) / Pfizer, Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche
Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study. (Hall A - Posters and Exhibits; Poster Bd #: 241) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1329;
P2
Clinical Trial Registration Number: NCT05849480 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Genentech Pfizer, Seagen (now a wholly owned subsidiary of Pfizer Inc.) AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Merck, Taiho Oncology Clinical Trial Registration Number: NCT02693535 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- SYN-818 / SynRx Therap
Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 305a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1314;
P1
Funded by Genentech Pfizer, Seagen (now a wholly owned subsidiary of Pfizer Inc.) AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Merck, Taiho Oncology Clinical Trial Registration Number: NCT02693535 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT07156253 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- EIK1005 / Eikon Therap
Phase 1/2 study of the novel Werner helicase inhibitor EIK1005 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including MSI-H or dMMR tumors. (Hall A - Posters and Exhibits; Poster Bd #: 299b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1299;
P1/2
Clinical Trial Registration Number: NCT07156253 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT07262619 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- opevesostat (MK-5684) / Merck (MSD)
Study design of OMAHA-015: A phase 2 basket study of steroidogenesis inhibitor opevesostat in participants with selected solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 306a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1267;
P2
Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Clinical Trial Registration Number: NCT06979596 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- calderasib (MK-1084) / Merck (MSD)
KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in KRAS G12C-mutant advanced solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 307a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1243;
P2
Clinical Trial Registration Number: NCT06979596 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT07209111 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Koselugo (selumetinib) / AstraZeneca
Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN. (Hall A - Posters and Exhibits; Poster Bd #: 247) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1226;
P3
Funded by AstraZeneca as part of an alliance between AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD). Clinical Trial Registration Number: NCT04924608 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- divarasib (RG6330) / Roche
First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non (Arie Crown Theater) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1008;
P1/2
Third-party medical writing assistance, under the direction of the authors, was provided by Tahmina S. Alam, MA, and Rebecca Benatan, BSc, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd. Clinical Trial Registration Number: NCT05789082 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial. (E350) - Apr 21, 2026 - Abstract #ASCO2026ASCO_1001;
Clinical Trial Registration Number: NCT05789082 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Tata Memorial Centre Research Administration Council, KamalUdwaadia Foundation (KUF), RJ Manudhane Foundation, Mankind Pharma, Nuclear Power Corporation of India Limited (NPCIL) Clinical Trial Registration Number: CTRI/2023/08/056715 The full, final text of this abstract will be available on May 30 at 08:00 AM EST.
- Tedopi (OSE 2101) / OSE Immunotherapeutics, Keytruda (pembrolizumab) / Merck (MSD)
The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial. (E450a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_976;
Funded by Tata Memorial Centre Research Administration Council, KamalUdwaadia Foundation (KUF), RJ Manudhane Foundation, Mankind Pharma, Nuclear Power Corporation of India Limited (NPCIL) Clinical Trial Registration Number: CTRI/2023/08/056715 The full, final text of this abstract will be available on May 30 at 08:00 AM EST. Funded by OSE Immunotherapeutics, SA ARCAGY-GINECO organization MSD France Clinical Trial Registration Number: 2024-516096-32-00 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- gotistobart (BNT316) / OncoC4, BioNTech
Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab. (E450a) - Apr 21, 2026 - Abstract #ASCO2026ASCO_974;
P2
Funded by Onco C4 Inc. Clinical Trial Registration Number: NCT05446298 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD), Imprime PGG (odetiglucan) / HiberCell
Phase II trial of pembrolizumab in combination with odetiglucan for patients with metastatic colorectal adenocarcinoma with liver-predominant disease. (Hall A - Posters and Exhibits; Poster Bd #: 439b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_946;
P2
Clinical Trial Registration Number: NCT05446298 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Merck Clinical Trial Registration Number: NCT07082439 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study. (Hall D2) - Apr 21, 2026 - Abstract #ASCO2026ASCO_776;
P3
Funded by The study was conducted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA in collaboration with Astellas Pharma Inc., Northbrook, IL, USA and Seagen Inc., Bothell, WA, USA, which was acquired by Pfizer in December 2023. Clinical Trial Registration Number: NCT03924895 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma. (Hall D2) - Apr 21, 2026 - Abstract #ASCO2026ASCO_773;
Clinical Trial Registration Number: NCT03924895 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Telehealth visits to support extended dosing of pembrolizumab and reduce health care visits: A pragmatic trial. (E350) - Apr 21, 2026 - Abstract #ASCO2026ASCO_765;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Cancer Institute National Institutes of Health and National Cancer Institute The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Imjudo (tremelimumab-actl) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study. (Hall D2) - Apr 21, 2026 - Abstract #ASCO2026ASCO_754;
P2
Funded by National Cancer Institute National Institutes of Health and National Cancer Institute The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by AstraZeneca Clinical Trial Registration Number: NCT06008093 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. (Hall B1) - Apr 21, 2026 - Abstract #ASCO2026ASCO_734;
P3
Funded by AstraZeneca Clinical Trial Registration Number: NCT06008093 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03036488 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study. (Arie Crown Theater) - Apr 21, 2026 - Abstract #ASCO2026ASCO_733;
P3
Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03036488 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Astellas Pharma Inc., Northbrook, IL, USA Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Seagen Inc., Bothell, WA, USA, which was acquired by Pfizer in December 2023 Clinical Trial Registration Number: EV-302 NCT04223856 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial. (Arie Crown Theater) - Apr 21, 2026 - Abstract #ASCO2026ASCO_731;
P3
Funded by Astellas Pharma Inc., Northbrook, IL, USA Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Seagen Inc., Bothell, WA, USA, which was acquired by Pfizer in December 2023 Clinical Trial Registration Number: EV-302 NCT04223856 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Funding for this study was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03142334 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Health-related quality of life (HRQOL) with pembrolizumab or observation for high-risk muscle-invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501). (Arie Crown Theater) - Apr 21, 2026 - Abstract #ASCO2026ASCO_721;
Funded by Funding for this study was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT03142334 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by U.S. National Institutes of Health Clinical Trial Registration Number: NCT03244381 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Jiataile (sacituzumab tirumotecan) / Merck (MSD)
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1 (Hall D2) - Apr 21, 2026 - Abstract #ASCO2026ASCO_706;
P3
Funded by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Clinical Trial Registration Number: NCT06448312 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD)
Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial. (S100bc) - Apr 21, 2026 - Abstract #ASCO2026ASCO_692;
P3
Clinical Trial Registration Number: NCT06448312 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Cancer Institute U.S. National Institutes of Health Clinical Trial Registration Number: NCT03914612 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.